Sanofi India Limited (IN:SANOFI)
:SANOFI
Want to see IN:SANOFI full AI Analyst Report?
SANOFI Stock Chart & Stats
₹4142.75
₹54.40(0.91%)
At close: 4:00 PM EST
₹4142.75
₹54.40(0.91%)
Day’s Range― - ―
52-Week Range₹3,151.05 - ₹6,399.95
Previous CloseN/A
Volume15.46K
Average Volume (3M)3.77K
Market Cap
₹73.55B
Enterprise Value₹70.90B
Total Cash (Recent Filing)₹3.13B
Total Debt (Recent Filing)₹209.00M
Price to Earnings (P/E)18.0
Beta0.80
Next Earnings
Jul 28, 2026EPS Estimate
44.4Next Dividend Ex-DateN/A
Dividend Yield4.73%
Share Statistics
EPS (TTM)146.55
Shares Outstanding23,030,000
10 Day Avg. Volume3,778
30 Day Avg. Volume3,766
Financial Highlights & Ratios
PEG Ratio6.96
Price to Book (P/B)12.56
Price to Sales (P/S)5.12
P/FCF Ratio22.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)168.05
Revenue Forecast (FY)₹19.50B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetSanofi India’s very low leverage provides durable financial resilience and capacity to fund investments, marketing or absorb shocks without strain. High ROE (~44% in 2025) shows efficient profit generation on equity, supporting sustainable shareholder returns and flexibility for strategic moves.
Strong Free Cash Flow GenerationFree cash flow closely tracking net income (FCF/net income ~0.85–0.96) indicates high earnings quality and real cash conversion. The strong 2025 FCF jump (+53.7%) enhances the company's ability to fund dividends, reinvest in core brands, and maintain financial flexibility over the medium term.
Durable Operating MarginsConsistently high operating profitability (EBIT ~22–25%) demonstrates structural margin strength from product mix and cost control. These margins create a long-term earnings buffer, enabling continued R&D/marketing spend and dividend capacity even if top-line growth is uneven.
Bears Say
Weak Revenue TrendRevenue has been choppy since 2022 with a 2025 decline (-4.1%) and multi-year negative growth (~-13%), eroding scale benefits. Persistent top-line weakness limits the company’s ability to leverage fixed costs, sustain higher R&D/marketing outlays, and organically restore long-term growth momentum.
Material Gross Margin CompressionA material fall in gross margin (from ~55–56% to ~39%) meaningfully reduces core earnings power. If driven by structural factors—pricing pressure, cost inflation, or adverse mix—it can persistently lower profitability and restrict the company’s ability to invest or maintain prior payout levels absent strategic margin recovery.
Equity Decline RisksA meaningful decline in equity over 2023–2025 can amplify ROE optics and may reflect distributions, write-downs, or other balance-sheet shifts. Shrinking equity reduces the capital base, potentially constraining long-term financial flexibility and making future growth or shock-absorption more difficult.
Sanofi India Limited News
SANOFI FAQ
What was Sanofi India Limited’s price range in the past 12 months?
Sanofi India Limited lowest stock price was ₹3151.05 and its highest was ₹6399.95 in the past 12 months.
What is Sanofi India Limited’s market cap?
Sanofi India Limited’s market cap is ₹73.55B.
When is Sanofi India Limited’s upcoming earnings report date?
Sanofi India Limited’s upcoming earnings report date is Jul 28, 2026 which is in 68 days.
How were Sanofi India Limited’s earnings last quarter?
Sanofi India Limited released its earnings results on Apr 28, 2026. The company reported ₹44.5 earnings per share for the quarter, missing the consensus estimate of ₹44.6 by -₹0.1.
Is Sanofi India Limited overvalued?
According to Wall Street analysts Sanofi India Limited’s price is currently Overvalued.
Does Sanofi India Limited pay dividends?
Sanofi India Limited pays a Semiannually dividend of ₹75 which represents an annual dividend yield of 4.73%. See more information on Sanofi India Limited dividends here
What is Sanofi India Limited’s EPS estimate?
Sanofi India Limited’s EPS estimate is 44.4.
How many shares outstanding does Sanofi India Limited have?
Sanofi India Limited has 23,030,000 shares outstanding.
What happened to Sanofi India Limited’s price movement after its last earnings report?
Sanofi India Limited reported an EPS of ₹44.5 in its last earnings report, missing expectations of ₹44.6. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Sanofi India Limited?
Currently, no hedge funds are holding shares in IN:SANOFI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singaporem and internationally. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, central nervous system, anti-infective, epilepsy, allergy and vitamins, anti-histamines, and minerals and supplements under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. The company also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
Technical Analysis
Abbott India Limited
―
Cipla Ltd
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
PFIZER LIMITED
―